SEGMENT INFORMATION - Adjustment to EBITDA (Details) - BRL (R$) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Notes and other explanatory information [abstract] | |||
| Fair Value - Biological Asset | R$ 1,516,458,000 | R$ 1,431,530,000 | R$ 1,989,831,000 |
| Loss from associates and joint ventures | (409,212,000) | (13,845,000) | (19,379,000) |
| Impairment of subsidiaries | (88,871,000) | ||
| Income from disposal and write-off of non-current assets | (386,396,000) | (169,284,000) | (232,143,000) |
| Provision/(reversals) for losses on ICMS credits (note 9.1) | (193,152,000) | (130,726,000) | (348,628,000) |
| Expenses on Asset Acquisition and Business Combinations | (82,426,000) | (34,065,000) | (25,171,000) |
| Write-off of wood inventory | (78,203,000) | (11,930,000) | (22,998,000) |
| Restructuring expenses | (59,725,000) | (1,205,000) | (8,974,000) |
| Others | 8,526,000 | 4,588,000 | 68,110,000 |
| Adjustments to EBITDA | R$ (209,947,000) | R$ (1,065,887,000) | R$ (1,264,428,000) |